All patients included in the BENEFIT 11 study can be considered to have started treatment with BETAFERON relatively early in the course of the disease . (Patients originally allocated to placebo started therapy on average (SD) 1.5 (0.7) years after their first clinical event suggestive of MS .)
At 11 years, there was no difference in disability between groups. Patients overall had relatively mild disability, with 69.8% of all patients being fully ambulatory with minor or no signs of disability (EDSS < 3) .1
Median EDSS increased from 1.5 at baseline to 2.0 at year 11 .
Furthermore, patients had a low risk of conversion to SPMS within 11 years: the Kaplan-Meier estimate of risk of secondary progressive MS (SPMS) was 5.9% overall .
Disability status of the patients included in the BENEFIT 11 study. Overall, the early BETAFERON treated patients experience relatively mild disability 11 years after disease onset [1,2]
Return to overview of BENEFIT long-term study outcomes
EDSS: Expanded Disability Status Scale
SD: standard deviation
- Kappos L et al. Neurology 2016; 87(10): 978-87. Return to content
- Kappos L et al. Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis 2014, LBP17. Return to content